Disease relevance of Alborixin

• Maduramicin or alborixin was administered beginning 4 weeks postinfection at 3 mg/kg of body weight per day [1].
• Evaluation of maduramicin and alborixin in a SCID mouse model of chronic cryptosporidiosis [1].
• Alborixin is similar to many other polyethers in that weight gains are adversely affected at drug levels essential for solid broad-spectrum anticoccidial activity [2].
• Alborixin, a polycyclic polyether ionophorous antibiotic, active against Gram-positive bacteria and fungi, was isolated from cultures of a strain of Streptomyces albus [3].

High impact information on Alborixin

• Nine of the 22 compounds, i.e., alborixin, lonomycin, nigericin, narasin, monensin and its methylated derivative, lasalocid and its bromo derivative, and gramicidin D, most specific to monovalent cations, were at least 35-fold more active in vitro against P. falciparum than against the two other mammalian cell lines [4].
• Monensin and maduramycin were significantly more efficacious than alborixin as a treatment for several species of Eimeria [2].
• These results suggest that the ionophores alter the intracellular ionic state of the myocardium, which may partly explain their positive inotropic effect and the greater effect of alborixin [5].
• The cardiovascular effects of two monocarboxylic inophores, grisorixin and alborixin, in anesthetized guinea-pigs [6].
• Grisorixin and alborixin are two monocarboxylic ionophorous antibiotics of nigericin group which form neutral complexes with monovalent cations, preferentially K+, so they are able to modify biological membrane permeability to these cations [6].

References